PuSH - Publikationsserver des Helmholtz Zentrums München: Requirements and expectations of high-quality biomarkers for atopic dermatitis and psoriasis in 2021 - a two-round Delphi survey among international experts.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Ziehfreund, S.* ; Tizek, L.* ; Hangel, N.* ; Fritzsche, M.C.* ; Weidinger, S.* ; Smith, C.* ; Bryce, P.J.* ; Greco, D.* ; van den Bogaard, E.H.* ; Flohr, C.* ; Rastrick, J.* ; Eyerich, S. ; Buyx, A.* ; Conrad, C.* ; Eyerich, K.* ; Zink, A.*

Requirements and expectations of high-quality biomarkers for atopic dermatitis and psoriasis in 2021 - a two-round Delphi survey among international experts.

J. Eur. Acad. Dermatol. Venereol. 36, 1467-1476 (2022)

Verlagsversion

DOI

PMC

	Open Access Hybrid

Abstract
Metriken
Zusatzinfos

BACKGROUND: Chronic inflammatory skin diseases such as atopic dermatitis (AD) and psoriasis (PSO) present major challenges in health care. Thus, biomarkers to identify disease trajectories and response to treatments to improve the lives of affected individuals warrant great research consideration. The requirements that these biomarkers must fulfill for use as practical clinical tools have not yet been adequately investigated. AIM: To identify the core elements of high-quality AD and PSO biomarkers to prepare recommendations for current biomarker research. METHOD: A cross-sectional two-round Delphi survey was conducted from August to October 2019 and October to November 2020. All participants were members of the BIOMAP project, an EU-funded consortium of clinicians, researchers, patient organizations and pharmaceutical industry partners. The first round consisted of three open-ended questions. Responses were qualitatively analyzed, and 26 closed statements were developed. For the second round, 'agreement' was assumed when the responses of ≥70% of the participants were ≥5 points on a 7-point Likert scale for each statement. Priority classification was based on mean scores (<20th-percentile=low, 20th-60th-percentile=medium, >60th-percentile=high). RESULTS: Twenty-one and twenty-six individuals participated in round one and two, respectively. From 26 statements that were included in round 2, 18 achieved agreement (8 concerning the performance, 8 for the purpose, and 2 on current obstacles). Seven statements were classified as high priority, e.g., those concerning reliability, clinical validity, a high positive predictive value, prediction of the therapeutic response, and disease progression. Another seven statements were assigned medium priority, e.g., those about analytical validity, prediction of comorbidities, and therapeutic algorithm. Low priority included four statements, like those concerning cost-effectiveness and prediction of disease flares. CONCLUSION: The core requirements that experts agreed on being essential for high-quality AD and PSO biomarkers, require rapid validation. Biomarkers can therefore be assessed based on these prioritized requirements.

Impact Factor

Scopus SNIP

Altmetric

9.228

0.000